<DOC>
	<DOCNO>NCT00343577</DOCNO>
	<brief_summary>Fabry disease rare disorder often kidney involvement increase urine protein excretion . Proteinuria recognize important risk factor progression chronic kidney disease . Our hypothesis use drug reduce urine protein excretion ( ACE inhibitor ARBs ) beneficial effect patient Fabry disease already receive enzyme replacement therapy . A longitudinal , observational study undertaken determine utility agent Fabry disease , realize agent primarily indicate reduce systemic blood pressure , patient Fabry disease relatively low blood pressure baseline .</brief_summary>
	<brief_title>Antiproteinuric Agents Fabry Disease</brief_title>
	<detailed_description>Fabry disease rare disorder often kidney involvement increase urine protein excretion . Proteinuria recognize important risk factor progression chronic kidney disease . Our hypothesis use drug reduce urine protein excretion ( ACE inhibitor ARBs ) beneficial effect patient Fabry disease already receive enzyme replacement therapy . A longitudinal , observational study undertaken determine utility agent Fabry disease , realize agent primarily indicate reduce systemic blood pressure , patient Fabry disease relatively low blood pressure baseline .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>genetically confirm Fabry disease institution commercially available agalsidasebeta s/p kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>proteinuria</keyword>
	<keyword>ARBs</keyword>
	<keyword>agalsidase-beta</keyword>
	<keyword>MDRD estimate GFR</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>